ATE147991T1 - Mittel zur entziehung von endprodukten der fortgeschrittenen glycosylation - Google Patents

Mittel zur entziehung von endprodukten der fortgeschrittenen glycosylation

Info

Publication number: ATE147991T1
Authority: AT; Austria
Prior art keywords: advanced glycosylation; end products; endproducts; extraction; agent
Prior art date: 1986-09-12

Application number

AT87113386T

Other languages

English (en)

Inventor

Helen Vlassara

Michael Brownlee

Anthony Cerami

Original Assignee

Univ Rockefeller

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-09-12

Filing date

1987-09-14

Publication date

1997-02-15

1987-09-14 Application filed by Univ Rockefeller filed Critical Univ Rockefeller

1997-02-15 Application granted granted Critical

1997-02-15 Publication of ATE147991T1 publication Critical patent/ATE147991T1/de

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Bioinformatics & Computational Biology (AREA)
Physiology (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)

AT87113386T 1986-09-12 1987-09-14 Mittel zur entziehung von endprodukten der fortgeschrittenen glycosylation ATE147991T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US90774786A	1986-09-12	1986-09-12

Publications (1)

Publication Number	Publication Date
ATE147991T1 true ATE147991T1 (de)	1997-02-15

Family

ID=25424576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT87113386T ATE147991T1 (de)	1986-09-12	1987-09-14	Mittel zur entziehung von endprodukten der fortgeschrittenen glycosylation

Country Status (7)

Country	Link
EP (1)	EP0259893B1 (de)
JP (1)	JP2644767B2 (de)
AT (1)	ATE147991T1 (de)
AU (1)	AU600306B2 (de)
DE (1)	DE3752007T2 (de)
ES (1)	ES2099059T3 (de)
GR (1)	GR3022382T3 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5811075A (en) *	1984-03-19	1998-09-22	The Rockefeller University	Method and agents for removing advanced glycosylation endproducts
JP2817219B2 (ja) *	1988-09-08	1998-10-30	武田薬品工業株式会社	カルバジン酸誘導体、その製造法及び製剤
KR920702230A (ko) *	1990-08-10	1992-09-03	오쯔까 아끼히꼬	간염예방·치료제
US5624804A (en) *	1991-12-20	1997-04-29	The Rockefeller University	Immunochemical detection of In vivo advanced glycosylation end products
AU3733293A (en) *	1992-02-25	1993-09-13	Alteon Inc.	Method and agents for promoting wound healing
JPH07508287A (ja) *	1992-05-15	1995-09-14	ザロックフェラーユニヴァーシティ	免疫応答を変調する方法および薬剤，並びにその使用
AU692237B2 (en) *	1994-02-03	1998-06-04	Picower Institute For Medical Research, The	Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6410598B1 (en)	1994-02-03	2002-06-25	Michael P. Vitek	Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6750209B1 (en) *	1995-09-12	2004-06-15	Kansas University Medical Center	Advanced glycation end-product intermediaries and post-amadori inhibition
MX2010012473A (es)	2008-05-23	2011-02-23	Siwa Corp	Metodos, composiciones y aparato para facilitar la regeneracion.
EP3511017A1 (de)	2010-09-27	2019-07-17	Siwa Corporation	Selektive entfernung von altersmodifizierten zellen zur behandlung von atherosklerose
US8721571B2 (en)	2010-11-22	2014-05-13	Siwa Corporation	Selective removal of cells having accumulated agents
CN102478569A (zh) *	2010-11-25	2012-05-30	苏州卫生职业技术学院	一种西红花酸对AGEs抑制效果的检测方法
US10584180B2 (en)	2014-09-19	2020-03-10	Siwa Corporation	Anti-AGE antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en)	2014-12-18	2019-07-23	Siwa Corporation	Product and method for treating sarcopenia
US9993535B2 (en)	2014-12-18	2018-06-12	Siwa Corporation	Method and composition for treating sarcopenia
EP3677598B1 (de)	2016-02-19	2022-04-06	Siwa Corporation	Verfahren und zusammensetzung zur behandlung von krebs, abtötung von metastasierenden krebszellen und verhinderung von krebsmetastasen mit einem antikörper gegen fortgeschrittene glykierungsendprodukte
WO2017181116A1 (en)	2016-04-15	2017-10-19	Siwa Corporation	Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en)	2016-06-23	2017-12-28	Siwa Corporation	Vaccines for use in treating various diseases and disorders
US10995151B1 (en)	2017-01-06	2021-05-04	Siwa Corporation	Methods and compositions for treating disease-related cachexia
US10961321B1 (en)	2017-01-06	2021-03-30	Siwa Corporation	Methods and compositions for treating pain associated with inflammation
US10858449B1 (en)	2017-01-06	2020-12-08	Siwa Corporation	Methods and compositions for treating osteoarthritis
US10925937B1 (en)	2017-01-06	2021-02-23	Siwa Corporation	Vaccines for use in treating juvenile disorders associated with inflammation
BR112019021471A2 (pt)	2017-04-13	2020-05-12	Siwa Corporation	Anticorpo monoclonal humanizado de produto final da glicação avançada
US11518801B1 (en)	2017-12-22	2022-12-06	Siwa Corporation	Methods and compositions for treating diabetes and diabetic complications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4665192A (en) *	1984-03-19	1987-05-12	The Rockefeller University	2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole

1987
- 1987-09-11 JP JP62228202A patent/JP2644767B2/ja not_active Expired - Fee Related
- 1987-09-11 AU AU78275/87A patent/AU600306B2/en not_active Ceased
- 1987-09-14 ES ES87113386T patent/ES2099059T3/es not_active Expired - Lifetime
- 1987-09-14 DE DE3752007T patent/DE3752007T2/de not_active Expired - Fee Related
- 1987-09-14 EP EP87113386A patent/EP0259893B1/de not_active Expired - Lifetime
- 1987-09-14 AT AT87113386T patent/ATE147991T1/de not_active IP Right Cessation
1997
- 1997-01-28 GR GR970400123T patent/GR3022382T3/el unknown

Also Published As

Publication number	Publication date
JPS63146833A (ja)	1988-06-18
AU600306B2 (en)	1990-08-09
DE3752007D1 (de)	1997-03-06
ES2099059T3 (es)	1997-05-16
EP0259893B1 (de)	1997-01-22
JP2644767B2 (ja)	1997-08-25
EP0259893A2 (de)	1988-03-16
GR3022382T3 (en)	1997-04-30
EP0259893A3 (de)	1989-06-14
AU7827587A (en)	1988-03-17
DE3752007T2 (de)	1997-05-28

Publication	Publication Date	Title
ATE147991T1 (de)	1997-02-15	Mittel zur entziehung von endprodukten der fortgeschrittenen glycosylation
MX169205B (es)	1993-06-24	Composicion para estimular el crecimiento del cabello
DE3689380D1 (de)	1994-01-27	Chemische Derivate von GHL-Cu.
IL96549A0 (en)	1991-09-16	Production of a biologically active protein
DE3482754D1 (de)	1990-08-23	Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
DE3650358D1 (de)	1995-09-07	Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
EP0308197A3 (de)	1989-11-29	Verfahren zur Stimulierung des Immunsystems
BR9500436A (pt)	1995-10-17	Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
EP0214254A1 (de)	1987-03-18	Melatoninhaltige mittel sowie deren verwendungen.
DE3684755D1 (de)	1992-05-14	Behandlung von tieren mit il-2, zubereitungen dafuer und ihre herstellung.
IT1199972B (it)	1989-01-05	Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale
NZ224116A (en)	1990-08-28	Compositions of interleukin-2 and fk565; method of stimulation of the immune system and package
IL88971A0 (en)	1989-08-15	Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
DE3770766D1 (de)	1991-07-18	Wirkstoffe zur anwendung bei der behandlung von tumoren.
ATE103608T1 (de)	1994-04-15	Chemische derivate von ghl-cu.
DE59304087D1 (de)	1996-11-14	Placentaextrakt und Verfahren zu seiner Herstellung
NZ216519A (en)	1989-02-24	Polycyclic compounds and pharmaceutical compositions
EP0158880A3 (en)	1986-01-08	Liposomes with inhalable allergens for treatment of allergies, method for their preparation and pharmaceutical compositions containing them
DE3380519D1 (en)	1989-10-12	Keratin derivative, process for its preparation and treatment composition containing it
FI871568A0 (fi)	1987-04-09	Arylsubstituerade naftyridin- och pyridopyrazinderivat.
EP0137499A3 (de)	1986-03-26	Verfahren zur Gewinnung von beta-Elemonsäure und diese enthaltende pharmazeutische Zubereitungen
IT8619458A0 (it)	1986-02-19	Prodotti per il trattamento del cuoio.
RU94013606A (ru)	1995-12-27	Гемостимулятор
RU93051204A (ru)	1997-02-27	Способ профилактики задержания последа у коров
IT1191844B (it)	1988-03-23	Procedimento di trattamento speciale per prodotti in sughero

Legal Events

Date	Code	Title	Description
1997-07-15	UEP	Publication of translation of european patent specification
2003-06-15	REN	Ceased due to non-payment of the annual fee